Digestion of biomolecules in biological matrices results in the formation of thousands of peptides that can interfere with your target molecule. In-silico peptide selection, use of surfactants, immunocapture, micro-elution...
Working from home is becoming an increasingly widespread practice, and FDAregulated industry is no exception. Even post-pandemic, it is likely that some staff in many companies will continue to work remotely for various...
As the COVID-19 pandemic spread across the USA in early 2020, many facilities had to reduce operations, preventing auditors from traveling to customer sites. Alturas Analytics developed processes to permit auditors to conduct...
About the Presenter Chad has over 20 years of related experience as an analytical scientist with over 17 years focused on bioanalysis at Alturas Analytics. This depth of experience in applied LC–MS/MS and GC–MS/MS,...
Chemical Inventory Management System (CIMS) is a custom-developed application by Alturas that has evolved from a small database for tracking of a few basic reagents to a system that currently functions as an electronic...
Bioanalysis of oligonucleotides by HPLC-MS/MS in support of regulatory submission has not been widely adopted. Several obstacles such as lack of sensitivity, adduct formation and analytical instrument dedication are barriers...
About the Presenter Jason Watts, Ph.D., is a scientist at Alturas Analytics Inc. focusing on HPLC-MS/MS techniques for method development, validation, and sample analysis of new chemical entities and biomolecules utilizing a...
About the Presenter Dr. Jennifer Zimmer is the Laboratory Director at Alturas Analytics, Inc. and has been working in the field of bioanalysis for over 20 years. She received her B.A. degree in English and...
With the recent adoption of the ICH M10 guidelines, the discussion shifts to the implementation of this latest technical document (Step 5). The ICH M10 provides recommendations on how to validate a bioanalytical assay for drug...
The adoption of ICH M10 will introduce several operational changes in the regulated bioanalytical laboratory. While most of these changes are minor, depending upon the stage of development for a drug discovery program, they...